U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H12O2
Molecular Weight 212.2439
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FELBINAC

SMILES

OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2

InChI

InChIKey=QRZAKQDHEVVFRX-UHFFFAOYSA-N
InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)

HIDE SMILES / InChI

Description

Felbinac, an active metabolite of fenbufen, is two times more potent than the parent drug. Felbinac is used topically to alleviate pain in the joints and muscles caused by injury or inflammation (Trixam 3% gel or foam). The drug is believed to exert its action by inhibiting COX-2 protein.

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Prostaglandin G/H synthase 2
48
Target ID: P35354
Gene ID: 5743.0
Gene Symbol: PTGS2
Target Organism: Homo sapiens (Human)
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TRAXAM

Approved Use

Traxam Gel is used for the relief of pain in the joints and muscles caused by injury or inflammation. It is used for the treatment of the following conditions: sprains, strains, bruising, rheumatic or arthritic conditions, frozen shoulder, tennis elbow or other joint injuries.
PubMed

PubMed

TitleDatePubMed
Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice.
1993 Nov
Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.
1993 Sep
Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice.
1994 Nov
Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid.
1997 Nov
Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide.
2001 Nov 21
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
2002 Jun
Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.
2004 Jul 2
Topical NSAIDs for acute pain: a meta-analysis.
2004 May 17
Percutaneous penetration of felbinac after application of transdermal patches: relationship with pharmacological effects in rats.
2008 Jan
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
2009
Validated LC-MS/MS assay for the determination of felbinac: Application to a preclinical pharmacokinetics study of felbinac trometamol injection in rat.
2009 Aug 15
Separation-oriented derivatization of native fluorescent compounds through fluorous labeling followed by liquid chromatography with fluorous-phase.
2009 Jun 15
Mechanisms of drug release in citrate buffered HPMC matrices.
2009 Mar 31
Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison.
2009 Sep 21
Design, synthesis and evaluation of mutual prodrug of 4-biphenylacetic acid and quercetin tetramethyl ether (BPA-QTME) as gastrosparing NSAID.
2010 Jun
The suitability of tris(hydroxylmethyl) aminomethane (THAM) as a buffering system for hydroxypropyl methylcellulose (HPMC) hydrophilic matrices containing a weak acid drug.
2010 Mar 15
2-(Biphenyl-4-yl)acetic acid (felbinac).
2010 Sep 25
Patents

Patents

05180731
2
05998470
4
07064135
2
07294637
3
07718672
2
07875636
2
08003641
2
08465851
2
JP1063552A
2
JP2001342130A
2
JP2001525058A
70
JP2006076941A
2
JP2008069127A
2
JPH01132544A
2
JPH11199515A
7
JPS59222409A
2

Sample Use Guides

In Vivo Use Guide
The usual dose is about one inch or 2.5cm (which is about one gram) of gel rubbed into the affected area two to four times a day.
Route of Administration: Topical
In Vitro Use Guide
A 0.12 mM concentration of felbinac (BPAA) produces almost complete inhibition of arachidonate-induced aggregation of blood platelets.
Name Type Language
FELBINAC
EP   INN   JAN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
4-Biphenylacetic acid
Systematic Name English
(1,1'-BIPHENYL)-4-ACETIC ACID
Systematic Name English
NSC-16284
Code English
DOLINAC
Brand Name English
LY-61017
Common Name English
FELBINAC [JAN]
Common Name English
TRAXAM
Brand Name English
felbinac [INN]
Common Name English
CL-83544
Code English
FELBINAC [USAN]
Common Name English
CL 83,544
Code English
LJC-10141
Code English
FELBINAC [MI]
Common Name English
Felbinac [WHO-DD]
Common Name English
LJC 10,141
Code English
NAPAGELN
Brand Name English
L-141
Common Name English
FELBINAC [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC M02AA08
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
WHO-VATC QM02AA08
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
Code System Code Type Description
RXCUI
262307
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY RxNorm
EVMPD
SUB07527MIG
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
SMS_ID
100000092655
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
DRUG BANK
DB07477
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
WIKIPEDIA
FELBINAC
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
NCI_THESAURUS
C80546
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
PUBCHEM
3332
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
DRUG CENTRAL
1141
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
ECHA (EC/EINECS)
227-233-2
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID0045389
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
NSC
16284
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
USAN
Y-88
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
CAS
5728-52-9
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
MERCK INDEX
m5255
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL413965
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
CHEBI
31597
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
FDA UNII
94WNJ5U8L7
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
INN
5831
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
DAILYMED
94WNJ5U8L7
Created by admin on Fri Dec 15 17:35:45 UTC 2023 , Edited by admin on Fri Dec 15 17:35:45 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of FELBINAC
SALT/SOLVATE (PARENT)
Structure of FELBINAC TROMETAMOL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966